Press Release:
Pennsylvania Father Receives Fourth Heart in Five Years
Total Artificial Heart Bridges Man to 2nd Heart Transplant After 310 Days

On July 2, 2008, Jim Hennigan received his Total Artificial Heart after suffering from chronic rejection of his donor heart transplant.
TUCSON, Ariz. – Sept. 1, 2009 – Over the last five years, Jim Hennigan has had four different hearts beating in his chest… the heart he was born with, two donor hearts and a Total Artificial Heart.
Hennigan received his newest donor heart on May 8, 2009, after living for more than 300 days with the SynCardia temporary CardioWest™ Total Artificial Heart.
“The Total Artificial Heart did a phenomenal job of keeping me healthy and active for more than 10 months,” said Hennigan. “My body got so used to the efficiency of the Total Artificial Heart that when I got the donor heart, it had a hard time keeping up.”
With the Total Artificial Heart, Hennigan was able to walk for up to an hour on the treadmill, ride the exercise bike and push his 450-lb driver around the hospital. The size and weight of the driver, which powered his Total Artificial Heart, kept him confined to the hospital while he waited for his matching donor heart.

On May 8, 2009, Hennigan was successfully bridged to his second donor heart transplant. Post-transplant, Hennigan, his son Zack and his daughter Kate enjoy a Phillies baseball game.
“The Total Artificial Heart is fantastic,” said Hennigan. “The downside was staying in the hospital the whole time. If I’d had a portable driver like the one approved for use in Europe, I would’ve been able to do things like watch my son’s basketball games, attend my daughter’s cheerleading competitions and get up in the morning to make them lunch for school.”
Hennigan received his first heart transplant in 2004, but over time, his body suffered from chronic rejection of his new heart. In 2008, doctors told Hennigan he would need another heart transplant.
When Hennigan arrived at the hospital on July 1, 2008, his kidneys and liver had shut down. He was placed on a feeding tube because his bowels were obstructed. To save Hennigan’s life, his doctors implanted the Total Artificial Heart to recover his vital organs and bridge him to a second donor heart transplant.
During 2008, 10% of people who were implanted with the Total Artificial Heart received the device because they were suffering from rejection of their donor heart transplant (read more).
###
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660
SynCardia temporary CardioWest™ Total Artificial Heart.


